ExBID effects on BP were analyzed in more depth by pooling data from patients with T2DM treated in six comparator controlled (PBO or insulin) clinical trials of 24 to 52 weeks duration (Fig. 9) [129]. The gene discussed is INS; the disease is type 2 diabetes mellitus.